Precigen - Stock Price History | PGEN

Historical daily share price chart and data for Precigen since 2021 adjusted for splits. The latest closing stock price for Precigen as of September 27, 2021 is 5.40.
  • The all-time high Precigen stock closing price was 68.71 on August 05, 2015.
  • The Precigen 52-week high stock price is 11.10, which is 105.6% above the current share price.
  • The Precigen 52-week low stock price is 3.36, which is 37.8% below the current share price.
  • The average Precigen stock price for the last 52 weeks is 6.91.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Precigen Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.7450 5.9100 10.5600 1.4600 10.2000 86.13%
2019 6.1791 7.1500 8.8300 4.1100 5.4800 -16.21%
2018 14.3264 13.4700 19.8700 6.5400 6.5400 -43.23%
2017 19.9325 24.8100 26.5000 11.3300 11.5200 -52.59%
2016 28.7573 29.1700 38.9000 21.3800 24.3000 -19.40%
2015 41.1521 26.1100 68.7100 26.0800 30.1500 9.52%
2014 23.5673 23.7400 36.8200 15.3000 27.5300 15.67%
2013 22.2422 24.7300 29.7000 17.6500 23.8000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.116B $0.103B
Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29